Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis

e15632 Background:Conventional chemotherapy has limited role in metastatic unresectable hepatocellular carcinoma (HCC). Sorafenib is currently approved for metastatic unresectable HCC. We wanted to assess the efficacy and safety of other tyrosine kinase inhibitors (TKI) targeting vascular endothelial growth factor (VEGF) receptor such as brivanib, linifanib and regorafenib in metastatic HCC. Methods: We have searched electronic databases Pubmed, Google scholar to identify published trials using brivanib, linifanib and regorafenib in HCC. The outcomes evaluated were overall survival, time to disease progression (TTDP) and adverse effects. Hazard ratios (HR) with their respective 95% confidence intervals (CI) were then computed using the appropriate model for categorical variables. We used STATA 13.0 and Comprehensive Meta Analysis 2.0 software for all analyses. Results: We included seven randomized control studies. A combined analysis of these seven randomised control trials showed improved overall survival (OS) in VEGF-TKI group when compared to placebo HR - 0.79; (95% CI 0.62-1.00). However, there was no significant survival benefit of the newer VEGF receptor inhibitors when compared to sorafenib (HR - 1.05; 95% CI 0.95-1.17). The time to disease progression (TTDP) was significantly better in VEGF-TKI group as compared to placebo (HR - 0.61; 95% CI 0.39-0.97). However, there was no significant difference in TTDP between VEGF-TKI group and Sorafenib (HR - 0.88; 95% CI 0.66-1.16). Adverse effects were noted to be higher in VEGF-TKI group when compared to placebo (HR- 1.07; 95% CI 1.01-1.13). Conclusions: Treatment with TKI targeting VEGF receptor is associated with a significant improvement in OS and TTDP with tolerable side effect profile. Inhibiting the VEGF receptor pathway could lead to improved outcomes in HCC.

Download Full-text

Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis

Hepatology Research ◽

10.1111/hepr.12568 ◽

2015 ◽

Vol 46 (1) ◽

pp. 58-71 ◽

Cited By ~ 20

Author(s):

Yulan Wang ◽

Tianxing Deng ◽

Li Zeng ◽

Weiqing Chen

Keyword(s):

Hepatocellular Carcinoma ◽

Radiofrequency Ablation ◽

Transcatheter Arterial Chemoembolization ◽

Meta Analysis ◽

Efficacy And Safety ◽

Arterial Chemoembolization

Download Full-text

Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis

Nutrition Journal ◽

10.1186/s12937-015-0056-6 ◽

2015 ◽

Vol 14 (1) ◽

Cited By ~ 14

Author(s):

Ling Chen ◽

Yaqin Chen ◽

Xiwei Wang ◽

Hong Li ◽

Hongmin Zhang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Amino Acid ◽

Meta Analysis ◽

Amino Acid Supplementation ◽

Efficacy And Safety ◽

Acid Supplementation ◽

Branched Chain Amino Acid ◽

Branched Chain

Download Full-text

Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis

Annals of Oncology ◽

10.1093/annonc/mdz422.063 ◽

2019 ◽

Vol 30 ◽

pp. ix63

Author(s):

Y. Yuan ◽

Y. Yun ◽

L. Lei ◽

N. Junsheng ◽

Z. Weiping

Keyword(s):

Hepatocellular Carcinoma ◽

Hepatic Resection ◽

Meta Analysis ◽

Efficacy And Safety

Download Full-text

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Frontiers in Oncology ◽

10.3389/fonc.2021.626984 ◽

2021 ◽

Vol 11 ◽

Author(s):

Shukang He ◽

Weichao Jiang ◽

Kai Fan ◽

Xiaobei Wang

Keyword(s):

Hepatocellular Carcinoma ◽

Group Treatment ◽

Checkpoint Inhibitors ◽

Meta Analysis ◽

Cochrane Library ◽

Control Group ◽

Efficacy And Safety ◽

Programmed Death Ligand 1 ◽

Programmed Death ◽

Programmed Death 1

BackgroundHepatocellular carcinoma (HCC) is often diagnosed at an advanced stage where only systemic treatment can be offered. The emergence of immune checkpoint inhibitors (ICIs) provides hope for the treatment of HCC. In this study, we performed a meta-analysis to provide evidence for the efficacy and safety of ICIs in the treatment of HCC.MethodsThe following databases and websites were searched: Embase, PubMed, Cochrane Library and ClinicalTrials.gov. The primary endpoints were response rate (RR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).ResultsFinally, twelve studies were included in this meta-analysis. When the corresponding outcome indicators and their 95% confidence intervals (CIs) were pooled directly, the overall RR, DCR, PFS and OS were 0.17 (0.15-0.19, I2 = 56.2%, P=0.009), 0.58 (0.55-0.61, I2 = 75.9%, P<0.001), 3.27 months (2.99-3.55, I2 = 73.0%, P=0.001), 11.73 months (10.79-12.67, I2 = 90.3%, P<0.001). Compared to the control group, treatment with ICIs significantly improved RR, PFS and OS, the OR and HRs were 3.11 (2.17-4.44, P<0.001), 0.852 (0.745-0.974, P=0.019) and 0.790 (0.685-0.911, P=0.001), respectively. However, no significant improvement in DCR was found in ICIs treatment in this meta-analysis.ConclusionHCC patients would benefit from ICIs treatment, however, more studies are needed in the future to provide more useful evidence for the treatment of HCC by programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors.

Download Full-text